Interleukin-10 prevents experimental allergic encephalomyelitis in rats

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Cytokine Biology

Background:

• Experimental allergic encephalomyelitis (EAE) is a T(h)1-mediated autoimmune disease targeting myelin proteins.
• EAE in rats typically shows spontaneous remission and develops lifelong resistance.
• Interleukin-10 (IL-10) is upregulated during EAE recovery, suggesting a therapeutic role.

Purpose of the Study:

• To investigate the effects of IL-10 on rat lymphoid cell functions in vitro.
• To evaluate IL-10's potential for preventing CNS autoimmune disease induction in vivo.

Main Methods:

• Assessed IL-10's impact on rat peritoneal macrophages, thymocytes, and encephalitogenic T lymphocytes in vitro.
• Administered IL-10 systemically during the initiation phase of EAE in Lewis rats.
• Monitored clinical disease, autoantibody production, T cell proliferation, and CNS/thymic changes.

Main Results:

• IL-10 suppressed MHC class II upregulation on macrophages and TNF production by T cells in vitro.
• Systemic IL-10 administration markedly suppressed EAE induction in Lewis rats.
• IL-10 treatment led to increased autoantibody production, sustained T cell proliferation, and reduced CNS/thymic pathology.

Conclusions:

• IL-10 demonstrates therapeutic potential for T(h)1-mediated CNS autoimmune diseases.
• IL-10 may be a viable treatment candidate for conditions like EAE.
• Further research into IL-10's role in neuroinflammation is warranted.